The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

14 articles for A Kinoshita


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
18
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.EBI
Ono Pharmaceutical
24
Discovery of G Protein-Biased EP2 Receptor Agonists.EBI
Ono Pharmaceutical
21
Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.EBI
Ono Pharmaceutical
12
Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.EBI
Ono Pharmaceutical
39
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.EBI
Setsunan University
18
Discovery of long-acting N-(cyanomethyl)-N-alkyl-L-prolinamide inhibitors of dipeptidyl peptidase IV.EBI
Minase Research Institute
21
Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.EBI
Ono Pharmaceutical
31
Discovery of new orally active prostaglandin D2 receptor antagonists.EBI
Ono Pharmaceutical
23
3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs.EBI
Minase Research Institute
23
Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists.EBI
Minase Research Institute
51
3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. part 2: optimization of the side chains to improve in vitro and in vivo potencies.EBI
Minase Research Institute
30
Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration.EBI
Minase Research Institute
51
Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase.EBI
Suntory
13
Synthesis and evaluation of a potent, well-balanced EPEBI
Ono Pharmaceutical